PRESS INFORMATION BUREAU पत्र सूचना कार्यालय GOVERNMENT OF INDIA भारत सरकार Asian Age, Delhi Wednesday 9th December 2015, Page: 15 Width: 4.53 cms, Height: 8.31 cms, a4, Ref: pmin.2015-12-09.42.183

Hetero gets DCGI nod for Hepatitis C

New Delhi: Drug maker Hetero has received approval from DCGI to market generic version of Gilead's Harvoni, a drug used in the treatment of Hepatitis C, in India. Hetero is the first company in India to receive the approval for the fixed-dose combination Ledipasvir-Sofosbuvir (90mg/400mg) from Drug Controller General of India (DCGI), the company said. Following the nonexclusive licensing agreement signed with Gilead Sciences in September last 1 year, to manufacture and 1 market chronic hepatitis C medicines, Hetero is all set to launch the Ledipasvir-31 Sofosbuvir. - PTI 14.1994

coortem